Truth, Disclosure and the Influence of Industry on the Development of NICE Guidelines: An Interview with Tim Kendall

The selective publication of clinical trials by the pharmaceutical industry and by academic investigators has long been a contentious area in medicine. Clinicians and scientists such as Iain Chalmers, one of the founders of the UK Cochrane Centre, have worked for over two decades to address the prob...

Full description

Bibliographic Details
Main Authors: McGoey, L, Kendall, T
Format: Journal article
Published: 2007
_version_ 1797058389383053312
author McGoey, L
Kendall, T
author_facet McGoey, L
Kendall, T
author_sort McGoey, L
collection OXFORD
description The selective publication of clinical trials by the pharmaceutical industry and by academic investigators has long been a contentious area in medicine. Clinicians and scientists such as Iain Chalmers, one of the founders of the UK Cochrane Centre, have worked for over two decades to address the problem of the under-reporting of research, suggesting that the failure to report clinical trials breaks ‘an implicit contract with the patients who had participated in them’, and should in some cases be treated as scientific misconduct (Chalmers, 1990, 20
first_indexed 2024-03-06T19:49:50Z
format Journal article
id oxford-uuid:23985080-4c20-4587-bed2-7b5ebbeb40b7
institution University of Oxford
last_indexed 2024-03-06T19:49:50Z
publishDate 2007
record_format dspace
spelling oxford-uuid:23985080-4c20-4587-bed2-7b5ebbeb40b72022-03-26T11:45:05ZTruth, Disclosure and the Influence of Industry on the Development of NICE Guidelines: An Interview with Tim KendallJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:23985080-4c20-4587-bed2-7b5ebbeb40b7Saïd Business School - Eureka2007McGoey, LKendall, TThe selective publication of clinical trials by the pharmaceutical industry and by academic investigators has long been a contentious area in medicine. Clinicians and scientists such as Iain Chalmers, one of the founders of the UK Cochrane Centre, have worked for over two decades to address the problem of the under-reporting of research, suggesting that the failure to report clinical trials breaks ‘an implicit contract with the patients who had participated in them’, and should in some cases be treated as scientific misconduct (Chalmers, 1990, 20
spellingShingle McGoey, L
Kendall, T
Truth, Disclosure and the Influence of Industry on the Development of NICE Guidelines: An Interview with Tim Kendall
title Truth, Disclosure and the Influence of Industry on the Development of NICE Guidelines: An Interview with Tim Kendall
title_full Truth, Disclosure and the Influence of Industry on the Development of NICE Guidelines: An Interview with Tim Kendall
title_fullStr Truth, Disclosure and the Influence of Industry on the Development of NICE Guidelines: An Interview with Tim Kendall
title_full_unstemmed Truth, Disclosure and the Influence of Industry on the Development of NICE Guidelines: An Interview with Tim Kendall
title_short Truth, Disclosure and the Influence of Industry on the Development of NICE Guidelines: An Interview with Tim Kendall
title_sort truth disclosure and the influence of industry on the development of nice guidelines an interview with tim kendall
work_keys_str_mv AT mcgoeyl truthdisclosureandtheinfluenceofindustryonthedevelopmentofniceguidelinesaninterviewwithtimkendall
AT kendallt truthdisclosureandtheinfluenceofindustryonthedevelopmentofniceguidelinesaninterviewwithtimkendall